Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

  • Poster presentation
  • Open access
  • Published:

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra


The durability of anti-tumor responses observed in patients treated with antibodies blocking PD-1 has provided a central role for these drugs in melanoma therapeutics. Identifying predictive biomarkers to aid therapeutic decision making is critical for realizing the full potential of these immunotherapies. We report on the development of a pre-treatment serum test to separate melanoma patients into two groups with significantly different outcomes following nivolumab therapy.


Pre-treatment serum samples were available from 119 patients in the NCT01176461 study (“SET1”) and 30 patients from an observational study (“SET2”) at two institutions. All patients had advanced un-resectable melanoma and received nivolumab.

Mass spectra were collected from all samples using the “deep MALDI” approach [1]. We identified 351 mass spectral peaks for use in classifier construction. SET1 was split into a development (DEV) (N=60) and an internal validation (VAL) (N=59) set. Deep learning methods were used to construct a classifier correlating with time-to-event data in a fashion similar to Roder et al [2] using only the DEV set. This classifier was validated on the VAL set and a test was constructed using the same procedure with the whole SET1 and performance evaluated on the independent SET2.


The test separated the populations into two groups, “Early”/”Late”, with worse/better outcome on nivolumab treatment. The hazard ratios (HRs) between Early and Late groups are presented in Table 1. Test classification groups did not show any association with available PD-L1 expression data and remained significant in multivariate analysis.

Table 1


We have constructed a test to identify melanoma patients most likely to have improved survival on nivolumab therapy. The test validated in an independent sample set with HR~0.3 and appears to be independent of PD-L1 expression. Some proteins used in the test are related to acute Phase reactions and the complement system. While further validation and protein identification studies are needed, this test may become a clinically useful predictive biomarker for nivolumab therapy.

This research was supported in part by the Yale SPORE in Skin Cancer, funded by the NCI, NIH, under award number 1 P50 CA121974 (R.H.)


  1. Duncan M: Proceedings of the 61st ASMS Conference on Mass Spectrometry and Allied Topics; June 8-9. 2013, Minneapolis (MN), MP 181

    Google Scholar 

  2. Roder J, et al: Proceedings of the Annual Meeting of the AACR; Apr 1-5. 2015, Philadelphia (PA), 5304-

    Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weber, J., Martinez, A.J., Roder, H. et al. Pre-treatment patient selection for nivolumab benefit based on serum mass spectra. j. immunotherapy cancer 3 (Suppl 2), P103 (2015).

Download citation

  • Published:

  • DOI: